Physician profile
Marcia Simmonds
NPI 1295914638
$9,737.95
in general payments reported to CMS, 2019-2025
36 companies · $2,244 in 2025
The $2,244 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,232 · 2022: $1,958 · 2023: $2,297 · 2024: $1,007 · 2025: $2,244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,548.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,547.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $1,168.77 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,055.02 | 2021-2025 | Imfinzi, Lynparza, Datroway |
| E.R. Squibb & Sons, L.L.C. | $843.10 | 2022-2025 | Reblozyl |
| Glaxosmithkline, LLC. | $599.16 | 2021-2022 | |
| Janssen Biotech, INC. | $580.58 | 2021-2025 | Rybrevant, Carvykti, Tecvayli |
| Daiichi Sankyo INC. | $532.85 | 2021-2025 | Enhertu |
| Genentech USA, INC. | $476.45 | 2021-2023 | Lunsumio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $382.14 | 2023-2025 | Jardiance |
| Eisai INC. | $352.94 | 2021-2023 | |
| Genzyme Corporation | $253.80 | 2022-2023 | |
| Stemline Therapeutics INC. | $243.45 | 2022-2023 | Orserdu |
| Genmab U.S., INC. | $238.79 | 2023-2025 | Epkinly |
| Gilead Sciences, INC. | $224.98 | 2021-2025 | Trodelvy |
| Puma Biotechnology, INC. | $221.22 | 2023-2024 | Nerlynx |
| Incyte Corporation | $217.21 | 2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $212.15 | 2021 | |
| Seagen INC. | $205.73 | 2023 | Tivdak, Tukysa |
| Beigene USA, INC. | $188.37 | 2022 | |
| Merck Sharp & Dohme LLC | $166.39 | 2023 | Verquvo |
| Legend Biotech USA INC. | $139.26 | 2024 | Carvykti |
| Boston Scientific Corporation | $127.90 | 2022-2025 | Farapulse, Watchman Flx, Versacross Access Solution |
| Bayer Healthcare Pharmaceuticals INC. | $125.01 | 2021 | |
| Emd Serono, INC. | $125.00 | 2023 | Bavencio |
| Pfizer INC. | $124.99 | 2024 | |
| Gt Medical Technologies, INC | $123.05 | 2023 | Gammatile |
| Alexion Pharmaceuticals, INC. | $121.84 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $121.82 | 2025 | Libtayo |
| Abbvie INC. | $119.62 | 2024 | |
| Servier Pharmaceuticals LLC | $112.33 | 2025 | |
| Amgen INC. | $110.68 | 2021-2025 | Repatha |
| Lilly USA, LLC | $90.16 | 2025 | |
| Stryker Corporation | $45.55 | 2025 | Flowtriever |
| Abbott Laboratories | $43.50 | 2021-2023 | Aveir |
| Siemens Medical Solutions USA, INC. | $20.04 | 2024 | Atellica Ch 930 Analyzer |
| Janssen Pharmaceuticals, INC | $13.03 | 2023 | Xarelto |
| Edwards Lifesciences Corporation | $11.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcia Simmonds listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.